Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16652151 | 0.88 | GPR119 (0.41) | STSGPR119ABL1RIN1 | |
| SCHEMBL9980847 | 0.85 | KMT2A (0.58) | STSKMT2AGPR119PTPN2PTPN1 | |
| SCHEMBL16632026 | 0.84 | HSD11B1 (0.46) | KMT2A | |
| SCHEMBL29480691 | 0.84 | KMT2A (0.51) | STSKMT2AGPR119PTPN2PTPN1 | |
| SCHEMBL21795781 | 0.84 | KMT2A (0.51) | STSKMT2AGPR119PTPN2PTPN1 | |
| SCHEMBL25326740 | 0.84 | P2RX3 (0.40) | STSGPR119 | |
| SCHEMBL31365790 | 0.84 | P2RX3 (0.40) | STSGPR119 | |
| SCHEMBL16632109 | 0.83 | HSD11B1 (0.47) | KMT2A | |
| SCHEMBL9980757 | 0.83 | GPR119 (0.62) | STSKMT2AGPR119PTPN2PTPN1 | |
| SCHEMBL28082009 | 0.83 | SLC18A3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4251618-A1 | 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115620-A1 | 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3057950-B1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-02 | — | — | EP | disclosed |
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-29 | — | — | US | disclosed |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-29 | — | — | US | disclosed |
| US-9403816-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| WO-2015057205-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | STS 133/4885KMT2A 1608/4885GPR119 721/4885 |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | RORC, RORB, RORA | STS 3534/4885KMT2A 995/4885GPR119 248/4885 |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | RORC, RORB, RORA | STS 2793/4885KMT2A 1278/4885GPR119 189/4885 |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | STS 3262/4885KMT2A 1790/4885GPR119 216/4885 |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | STS 3169/4885KMT2A 1176/4885GPR119 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.